Generate Biomedicines is trading 5.38% higher at $16.25 in pre-market, with no clear catalyst identified for the September 30 move. - Available search results did not identify a fresh company announcement or other clear catalyst. - Recent coverage discussed the company’s September 23 healthcare forum, but that is not evidence of a new catalyst today. - Supplied major-index moves are small and mixed, so broader-market sentiment does not clearly explain the gain.